Overall rank by patents
#27,121
Across all tracked assignees
USPTO PatentsView assignee record - 10 granted patents across 4 technology areas, active 2016–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61L (METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES;).
The verdict
Puracath holds 10 US patents across 4 technology areas, rank #27,121 of 50,000 tracked assignees.
Puracath Medical, Inc. has been granted 10 US utility patents between 2016 and 2025, placing Puracath Medical, Inc. at rank #27,121 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 23.3 claims per patent with primary concentration in A61L (METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES;). As a US Corporation, Puracath Medical, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Puracath sits between Proxy Biomedical Limited (10 patents, rank #27,117) and Pacific Coast Building Products, Inc. (10 patents, rank #27,125) - the closest US assignees by grant volume. The composite Innovation Score of 36.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 8 grants, compared with 2 in the 2015–2019 window, a +300% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Puracath Medical, Inc.'s 23.3 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Puracath Medical, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
PROXY BIOMEDICAL LIMITED
10 patents
PSIVIDA US, INC.
10 patents
PSP
10 patents
PTT Exploration and Production Public Company Limited
10 patents
PYXIS CF PTE. LTD.
10 patents
Pablo, Inc.
10 patents
Pacific Bearing Corp.
10 patents
Pacific Coast Building Products, Inc.
10 patents
PURACATH MEDICAL, INC.
10 patents
What this shows Puracath holds 10 patents at rank #27,121, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #27,121 in granted patent volume.
Other assignees with the most granted patents in Puracath's primary technology class.
Puracath's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
36 Top 48% higher than 52% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 2 | 20.0% |
| 2021 | 3 | 30.0% |
| 2022 | 1 | 10.0% |
| 2023 | 1 | 10.0% |
| 2024 | 1 | 10.0% |
| 2025 | 2 | 20.0% |
Top 4 of 4 technology areas
Overall rank by patents
#27,121
Across all tracked assignees
36.0 out of 100
How to use this portfolio
Puracath's 10 grants land it in the top 48% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.